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http://dx.doi.org/10.1016/j.hkjn.201Summary Background: Obesity is an independent risk factor for renal disease. Microalbumi-
nuria (MA) is the first sign of renal injury. Tubular dysfunction may present early in obesity but
this has not been well studied. This study aimed at assessing glomerular and tubular dysfunc-
tions and their relationship to adiponectin and oxidative stress in obese participants.
Methods: This study was conducted on 60 participants. Group 1 included 20 healthy individuals
as controls, Group 2 included 20 obese individuals with normal albumin excretion rate (AER),
and Group 3 included 20 obese individuals with increased AER. Clinical assessment, anthropo-
metric measurements, and laboratory investigations included: estimation of serum high-
density lipoprotein (HDL)-cholesterol, urinary albumin to creatinine ratio, and calculation of
estimated glomerular filtration rate. Serum adiponectin, thiobarbituric acid-reactive
substances (TBARs) as a marker of oxidative stress, and urinary gamma glutamyl transferase
(UGGT) as a marker of tubular function were also estimated.
Results: The estimated glomerular filtration rate was higher in obese individuals with normal
AER and significantly lower in those with abnormal AER compared to controls. Adiponectin was
lower and TBARs and UGGT significantly higher in obese individuals with normal and abnormal
AER than controls. Adiponectin was negatively correlated with TBARs, AER, and UGGT. There
were positive correlations between TBARs and both AER and UGGT. HDL-cholesterol was posi-
tively correlated with adiponectin and negatively correlated with TBARs and UGGT.
Conclusion: Glomerular and tubular dysfunctions in obese individuals are related to low adipo-
nectin and HDL-cholesterol levels and to oxidative stress. Tubular dysfunction precedes MA, so
UGGT may be used as an early marker for obesity related nephropathy.earch Institute, Alexandria University, 10 Kamal el Deen Salah Street, Smoha, Alexandria, Egypt.
ahoo.com (E.W. Gaber).
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Renal tubular dysfunction in obesity 39背景: 肥胖症是腎病的獨立危險因子，微白蛋白尿症(MA)則是腎損傷的最早期徵兆。腎小管功能
障礙可能早於肥胖症初期出現，但這尚未獲得充分的研究探討。本研究旨在評估肥胖症患者間的
腎小球與腎小管功能，並調查後兩者與adiponectin及氧化壓力的關係。
方法: 研究對象為60人，包括健康對照組的20人(組I)、20位白蛋白排泄率(AER)正常的肥胖症患
者(組II)、及20位AER過高的肥胖症患者(組III)。所有人均接受了全面的體格與臨床評估、及醫學
檢驗，後者包括：血清HDL-cholesterol、尿液albumin與creatinine比例、及腎絲球過濾率估算
值(e-GFR)。此外，氧化壓力指標包括血清adiponectin、thiobarbituric acid-reactive substances
(TBARs)；腎小管功能指標則為尿液的gamma glutamyl transferase (UGGT)濃度。
結果: 相比於對照組，較高的e-GFR出現在AER正常的肥胖症患者間；明顯較低的e-GFR則出現在
AER異常的肥胖症患者之中。同時，不論AER是否正常，肥胖症患者的adiponectin濃度較低，
TBARs與UGGT則明顯較高。Adiponectin與TBARs、AER、及UGGT三者之間存在負相關的關係；
TBARs則與AER及UGGT兩者呈正相關。此外，HDL-cholesterol與adiponectin呈正相關，與TBARs
及UGGT兩者則呈負相關的關係。
結論: 肥胖症患者的腎小球與腎小管功能障礙與較低的adiponectin及HDL-cholesterol有關，亦與
氧化壓力有關。腎小管功能障礙在MA之前出現，因此UGGT可以作為肥胖症相關腎病變的早期指
標。Introduction
The incidence and prevalence of obesity have increased
over the past 2 decades and become a worldwide public
health problem. Several epidemiologic studies have clearly
demonstrated that obesity is an independent risk factor for
the onset, aggravated course, and poor outcomes of
chronic kidney disease (CKD).1 Obesity is associated with
various functional and structural lesions of the kidney. The
spectrum ranges from glomerulomegaly with or without
focal segmental glomerulosclerosis, to diabetic nephrop-
athy, to carcinoma of the kidney and nephrolithiasis.2
Obesity is associated with worsening albuminuria,
proteinuria, and end-stage renal disease (ESRD). Therefore,
early screening of CKD for obese individuals may lead to
more successful intervention and management of CKD, and
is beneficial to prevent further renal damage. Micro-
albuminuria (MA) is the current first sign of renal injury, as
well as the predictor of progression to ESRD.3
Adiponectin is a 30-kDa plasma protein primarily secreted
by adipocytes. Plasma adiponectin levels are reduced with
increasing visceral obesity and tightly correlate with insulin
resistance and development of Type 2 diabetes.4 Adipo-
nectin has been shown to support normal podocyte func-
tion.5 Weight gain-induced decline in adiponectin may
disrupt podocyte function leading to albuminuria.6
Oxidative stress plays an important role in the patho-
genesis and progression of many renal diseases.7 It has been
reported that, obesity is not only associated with increased
oxidant stress but also with reduced antioxidant defense
mechanisms, including decreased erythrocyte glutathione
and glutathione peroxidase.8 Podocytes are known to be
particularly susceptible to oxidative injury and reactive
oxygen species (ROS) play a critical role in podocyte injury
and glomerular dysfunction.9
Increased oxidative stress in obesity contributes to adi-
pokine dysregulation, inflammation, and insulin resistance.10
Oxidative stress has been linked with adiponectin defi-
ciency.11 Evidence indicates that thiobarbituric acid reactive
substances (TBARs) can be used as a reliable index of oxida-
tive stress in man because they reflect lipid peroxidation.12
Many previous studies on obesity related nephropathy
have focused on functional and structural changes in theglomeruli and a little is known about the presence of
tubular dysfunction. Obese individuals with minimal
apparent nephropathy, as evidenced by MA, have signifi-
cant alteration in tubular functions .13
Tubular damage as suggested by enzymuria and tubular
proteinuria is a recognized feature of glomerulonephritis
with clinical albuminuria and diabetic nephropathy.14
Moreover, it has been recognized that changes within
tubulointerstitium are more important than glomerulop-
athy in terms of renal prognosis in patients with CKD.15
Gamma glutamyl transferase (GGT) is an enzyme located
in the brush border of the proximal convoluted tubules of
the kidney. Urinary GGT level has been reported to increase
during renal tubular damage and can be used as a marker of
tubular function.16 Tubular dysfunction may present early
in obesity but this has not been well studied. This study
aimed at assessing glomerular and tubular dysfunctions and
their relationship to adiponectin and oxidative stress in
obese individuals.Participants and methods
After approval of the Ethical Committee of the Medical
Research Institute, the present study was conducted on 60
unknown individuals directly recruited from the outpatient
clinic of the Internal Medicine Department of the Medical
Research Institute, Alexandria, Egypt. Written informed
consents were taken from all participants and they were
divided into three groups:
 Group 1 included: 20 apparently healthy volunteers (10
females and 10 males) with body mass index (BMI)
<25 kg/m2.
 Group 2 included: 20 obese individuals (10 females and
10 males) with BMI > 30 kg/m2 and normal albumin
excretion rate (AER).
 Group 3 included: 20 obese individuals (12 females and
8 males) with BMI > 30 kg/m2 and increased AER.
All individuals involved in this study were free from dia-
betes,chronic liverdisease, connective tissuedisease, cardiac
diseases, respiratory diseases, infections, and malignancy.
40 E.W. Gaber et al.To all studied participants the followings were done:
1. Detailed history taking and thorough clinical examina-
tion with special stress on clinical manifestations of
renal disease.
2. Anthropometric measurements included: triceps skin
fold, mid-arm circumference, mid-arm muscle circum-
ference, waist circumference (WC) and calculation of
BMI.17
3. Twelve-lead electrocardiogram.
4. Ultrasonography of kidneys
5. Laboratory investigations included: estimation of serum
levels of fasting and two hours postprandial glucose
(FSG, PPG),18 serum uric acid,18 cholesterol [total,
high- and low-density lipoprotein-cholesterol (HDL-C,
LDL-C)], and triglycerides (TG)18; estimation of serum
activities of alanine aminotransferase, aspartate ami-
notransaminase, and GGT.18 Renal function tests
included: complete urine analysis, estimation of serum
urea and creatinine, and calculation of estimated
glomerular filtration rate (eGFR) using the Cockcroft-
Gault equation18; estimation of urinary albumin to
creatinine ratio (ACR) to assess AER19; estimation of
urinary GGT enzyme (UGGT) by enzyme linked immu-
nosorbant assay (ELISA) technique as a marker of renal
tubular damage.20 All these analyses were conducted
on the Olympus AU400 clinical chemistry analyzer
(Olympus, Tokyo, Japan). Estimation of serum thio-
barbituric acid (TBA)-reactive substances (TBARs), as
a marker of the oxidative stress,21 the TBARs assay
measures the amount of malondialdehyde and
malondialdehyde-like substances formed by the lipid
peroxidation process. Deproteinization of the EDTA
plasma by trichloroacetic acid was done and malon-
dialdehyde in the protein free supernatant was allowed
to react with TBA in acidic media in a boiling water bath
to form a rosy colored product that is measured spec-
trophotometrically against TBA reagent blank at 532 nm
and compared with a standard solution similarly
treated. Estimation of serum adiponectin level: using
a noncompetitive sandwich ELISA (Cat#: ELH-
ADIPONECTIN-001; RayBiotech, Inc., Norcross, GA,
USA).22
The serum samples, standards, and controls were pipetted
into microplate wells coated with antihuman adiponectin
antibodies. After incubation and washing steps, biotinylated
antihuman adiponectin antibodies were added. After the
second incubationandwashing steps, horseradishperoxidase-
conjugated streptavidinwas added.After the third incubation
andwashing steps, a tetramethylbenzidine substrate solution
was added followed, after incubation, by adding a stopping
solution. The yellow color developed was proportional to
the amount of adiponectin bound. The intensity of this
color was measured at 450 nm and the concentration of
adiponectin was obtained from a standard curve.Statistical analysis
Data were analysed using SPSS software. Results are
expressed as means and standard deviations (SD).Abnormally distributed data were analysed by Mann-
Whitney test. Statistical comparisons between two
percentages were made by using the Chi-square test.
Statistical comparisons of three groups were made using
one-way ANOVA test with posthoc comparisons. The
correlations between different variables were evaluated by
Pearson or Spearman correlation coefficients according to
the distribution of variable (continuous or discontinuous
quantitative variables respectively). Statistical significance
was assessed at p < 0.05. All calculated p-values were two-
tailed.
Multiple regression analyses were carried out to inves-
tigate the relationship between dependent variables (BMI,
adiponectin, TBARs, and UGGT) and several other antici-
pated independent predictor variables (WC, blood pres-
sure, eGFR, ACR, lipid profile, uric acid, and FSG). The
backward stepwise method was used to choose only the
most significant predictors of them to be included into the
final multiple regression models. The nonsignificant
predictor variables were sequentially removed one by one.Results
The clinical and laboratory data are presented in
Tables 1e10. The mean systolic blood pressure, FSG, PPG,
total cholesterol, LDL-C, TG, and uric acid were signifi-
cantly higher in obese individuals than controls. The mean
HDL-C was significantly lower in obese individuals than
controls (42.45  5.4 and 43.00  8.44 vs. 50.85  9.57 mg/
dL, pZ 0.002). There were significant positive correlations
between BMI and both WC and blood pressure and between
BMI and ACR in obese individuals with abnormal AER. The
eGFR was higher in obese individuals with normal AER
compared to controls and was significantly lower in obese
individuals with abnormal AER compared to obese individ-
uals with normal AER and controls (87.62  8.22 vs.
99.23  13.54 and 96.67  7.22 mL/min, p Z 0.001).
The mean serum adiponectin level was lower in obese
individuals than controls, but this lower adiponectin level
was statistically significant only in obese individuals with
abnormal AER compared to controls (4.04  2.1 vs.
6.04  3.39 mg/ml, p Z 0.049). The median serum adipo-
nectin levels were nonsignificantly higher in females of
each of the three studied groups than males. The mean
TBARs level was significantly higher in obese individuals
with normal and abnormal AER compared to controls
(15.45  3.99 and 15.65  4.84 vs. 8.05  1.54 mmol/l,
p < 0.0001). The mean UGGT level was significantly higher
in obese individuals with normal and abnormal AER than
controls (61.3  25.87 and 77.6  33.51 vs.
44.85  14.06 IU/l, p Z 0.001). Serum adiponectin level
was negatively correlated with BMI, WC, systolic and dia-
stolic blood pressure, TBARs, and UGGT and positively
correlated with HDL-C. There was a significant negative
correlation between serum adiponectin and ACR in obese
individuals with abnormal AER. There were significant
positive correlations between serum TBARs and each of
BMI, WC, systolic and diastolic blood pressure, and UGGT
and a significant negative correlation between serum TBARs
and HDL-C. Also, there was a significant positive correlation
between TBARs and ACR in obese individuals with abnormal
Table 1 Some clinical data of all studied obese and control participants.
Parameter Group 1 (G1) Group 2 (G2) Group 3 (G3) p G1/G2 GI/G3 G2/3
Age (y) 38.90  7.03 38.95  6.72 42.70  6.33 0.130 NS NS NS
SBP (mmHg) 116.0  9.95 130.50  13.17 133.0  13.02 <0.001 Sig Sig NS
DBP (mmHg) 76.0  5.03 80.0  8.58 81.0  10.71 0.149 NS NS NS
BMI (kg/m2) 23.25  1.42 37.87  6.31 39.64  3.17 <0.0001 Sig Sig NS
TSF (cm) 0.72  0.09 2.91  0.49 3.04  0.31 <0.0001 Sig Sig NS
MAC (cm) 32.10  3.46 45.30  7.55 48.55  4.90 <0.0001 Sig Sig NS
MAMC (cm) 29.37  3.46 35.79  6.25 38.97  4.22 <0.0001 Sig Sig Sig
WC (cm) 83.15  2.83 123.35  12.73 122.55  8.64 <0.0001 Sig Sig NS
BMI Z body mass index; DBP Z diastolic blood pressure; MAC Z mid arm circumference; MAMC Z mid arm muscle circumference;
SBP Z systolic blood pressure; SD Z standard deviation; TSF Z triceps skin fold; WC Z waist circumference.
Renal tubular dysfunction in obesity 41AER. The UGGT was positively correlated with BMI, WC and
ACR and negatively correlated with HDL-C.
The final multiple regression analyses with BMI (an
indicator of obesity) as the dependent variable revealed
that, in all studied participants, systolic blood pressure,
uric acid and TBARS were significant positive predictors of
obesity. In obese individuals with normal AER (Group 2),
TBARS were significant positive predictors of obesity and in
obese individuals with increased AER (Group 3); adipo-
nectin was a significant negative predictor of obesity. On
using adiponectin as a dependent variable, in all studied
participants TBARs were negative predictors. In Group 2,
WC, ACR, and cholesterol were negative predictors, and in
Group 3, TBARs, ACR, and LDL-C were negative predictors,
while HDL-C was a positive predictor. On using TBARs as
a dependent variable, in all studied participants adipo-
nectin and HDL-C were negative predictors, while BMI,
systolic blood pressure and UGGT were positive predictors.
In Group 2, HDL-C was a negative predictor, while BMI,
systolic blood pressure, LDL-C, triglycerides, ACR, and
UGGT were positive predictors. In Group 3 adiponectin and
eGFR were negative predictors, while BMI, systolic blood
pressure, FSG, cholesterol, triglycerides, and UGGT were
positive predictors. On using UGGT as a dependent variable,Table 2 Fasting and post prandial serum glucose and lipid profi
Parameter Group 1 (G1) Group 2 (G2) Grou
FSG (mg/dL)
Mean  SD 88.80  8.07 95.45  8.20 98.
PPSG (mg/dL)
Mean  SD 106.35  4.75 112.35  10.19 114.
TC (mg/dL)
Mean  SD 164.20  2.23 204.65  29.45 208.
HDL-C (mg/dL)
Mean  SD 50.85  9.57 42.45  5.40 43.
LDL-C (mg/dL)
Mean  SD 96.70  20.65 139.60  28.82 132.
TG (mg/dL)
Mean  SD 93.55  32.37 119.90  35.24 129.
FSGZ fasting serum glucose; HDL-CZ High density lipoprotein chole
prandial glucose; TC Z total cholesterol.in all studied participants WC and TBARs were positive
predictors. In Group 2 WC, ACR, cholesterol, and TBARs
were positive predictors and in Group 3 LDL-C, ACR, and
TBARs were positive predictors.Discussion
Obesity represents an underestimated risk factor for renal
disease. Obese patients are three times more likely to
develop renal disease than nonobese patients.23 In this
work, obese individuals had a significant association
between increased overall obesity as measured by BMI and
increased visceral fat as measured by WC. In addition, they
have higher levels of systolic blood pressure, FSG, PPG,
total cholesterol, LDL-C, TG, and uric acid and lower level
of HDL-C than controls. On using final multiple regression
analysis in all the studied participants, systolic blood
pressure and uric acid were significant positive predictors
of obesity. These findings indicate that obesity is accom-
panied by one or more of the components of metabolic
syndrome, which is strongly associated with the develop-
ment of renal disease.24 These results are consistent with
the results of many other studies.25e27le of all studied obese and control participants.
p 3 (G3) p G1/G2 G1/G3 G2/3
40  7.96 0.001 Sig Sig NS
20  11.40 0.025 Sig Sig NS
20  35.67 <0.0001 Sig Sig NS
00  8.44 0.002 Sig Sig NS
25  32.21 <0.0001 Sig Sig NS
20  38.47 0.007 Sig Sig NS
sterol; LDL-CZ Low density lipoprotein cholesterol; PPGZ post
Table 3 Serum urea, creatinine, estimated glomerular filtration rate and serum uric acid of all studied participants.
Parameter Group 1 (G1) Group 2 (G2) Group 3 (G3) p G1/G2 G1/G3 G2/3
Urea (mg/dL)
Mean  SD 24.35  4.18 25.40  4.19 28.75  8.37 0.056 NS NS NS
Cr (mg/dL)
Mean  SD 0.81  0.10 0.85  0.12 0.84  0.10 0.449 NS NS NS
eGFR (mL/min)
Mean  SD 96.67  7.22 99.23  13.54 87.62  8.22 0.001 NS Sig Sig
UA (mg/dl)
Mean  SD 4.74  0.58 5.45  0.73 5.97  0.48 <0.0001 Sig Sig Sig
Cr Z serum creatinine; eGFR Z estimated glomerular filtration rate; UA Z uric acid.
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adipocytokines (leptin, tumor necrosis factor-a, adipo-
nectin, free fatty acids, and resistin) that play important
roles in the pathogenesis of insulin resistance and associ-
ated metabolic complications such as impaired glucose
tolerance, dyslipidemia, and hypertension.28
Our study demonstrated that, eGFR was higher in obese
individuals with normal AER and was significantly lower in
those with increased AER. A similar association between
albuminuria and GFR has been reported in other stud-
ies.29e31 Previous experimental and clinical studies of
obesity confirmed the presence of early hemodynamic
changes, which are characterized by an increase GFR and
accompanied by variable increments in albumin excre-
tion.30,31 Then, once macroalbuminuria sets in, GFR begins
to decline.
The first sign of renal damage in obesity is MA, which
indicates the potential risk of the progression to renal
insufficiency.3 In the current study there was a significant
positive correlation between BMI and ACR in obese indi-
viduals with abnormal AER. Other studies have supported
this association.32,33 The mechanism of obesity-associated
proteinuria is unclear but may include hyperfiltration,
increased renal venous pressure, glomerular hypertrophy,
hyperlipidemia, and increased synthesis of vasoactive and
fibrogenic substances, including angiotensin II, insulin,
leptin, and transforming growth factor-b1.34Table 4 Urinary albumin/creatinine ratio and gamma glutamyl
and adiponectin of all studied participants.
Parameter Group 1 (G1) Group 2 (G2) Group
ACR (mg/g)
Mean  SD 28.24  1.12 27.10  1.32 191.7
UGGT (IU/L)
Mean  SD 44.85  14.06 61.30  25.87 77.6
TBARS (mM)
Mean  SD 8.05  1.54 15.45  3.99 15.6
Adiponectin (mg/mL)
Mean  SD 6.04  3.39 4.39  2.38 4.0
ACR Z urinary albumin/creatinine ratio; TBARS Z serum thiobarbit
transferase.In this work, although plasma adiponectin levels were
higher in females than males, yet these levels did not reach
the level of significance due to the small sample size. The
higher adiponectin levels in females have been reported in
other studies.35 This can be explained by the well-known
difference between males and females in fat distribution
and metabolism,36 and the selective inhibition of the
secretion of high molecular weight adiponectin by
testosterone.37
In the present study, the mean adiponectin level was
lower in obese individuals than controls and was nega-
tively correlated with BMI and WC. In addition, the final
multiple regression analysis revealed that adiponectin was
a significant negative predictor of obesity (BMI) in obese
individuals with increased AER, and WC was a negative
predictor of adiponectin in obese individuals with normal
AER. Adiponectin reduction in obesity has been docu-
mented in many other studies.38,39 Reduced adiponectin
level in obesity can be explained by the presence of the
chronic inflammatory state in obesity with increased
production of proinflammatory cytokines such as tumor
necrosis factor-a, and interleukins-6 and -18 that reduce
adiponectin gene expression with subsequent decreased
adiponectin secretion.40 In addition, increased fat mass
results in a hypoxic microenvironment and suppression of
adiponectin gene expression via the hypoxia-induced
factor-1.41transferase and serum thiobarbituric acid reactive substances
3 (G3) p G1/G2 G1/G3 G2/3
0  60.57 <0.0001 NS Sig Sig
0  33.51 0.001 Sig Sig NS
5  4.84 <0.0001 Sig Sig NS
4  2.10 0.049 NS Sig NS
uric acid reactive substances; UGGT Z urinary gamma glutamyl
Table 5 Adiponectin levels in males and females of the three studied groups.
Group 3 Group 2 Group 1
Female
(n Z 16)
Male
(n Z 4)
Female
(n Z 10)
Male
(n Z 10)
Female
(n Z 10)
Male
(n Z 10)
Adiponectin
(mg/mL)
1.32e7.07 2.23e8.74 2 .09e5.58 1.59e10.77 1.93e12.76 2.67e12.88 Range
4.51 3.58 4.72 2.89 5.65 4.73 Median
0.705 0.364 0.597 P
P value for ManndWhitney p value between males and females in each group
Renal tubular dysfunction in obesity 43Oxidative stress (OS) plays an important role in a variety
of renal diseases including glomerulonephritis and can
contribute to albuminuria.7,9 In the present study, TBARs
were significantly higher in obese individuals than controls.
In addition, the final multiple regression analysis confirmed
that TBARs and BMI were significant positive predictors of
each other in all participants and in both obese groups with
normal and increased AER. These data are in agreement
with other previously published data.42,43 Obesity has been
described as a state of chronic OS. There are several
possible contributors to OS in obesity, including hypergly-
cemia, increased muscle activity to carry excessive weight,
elevated tissue lipid levels, inadequate antioxidant
defenses, chronic inflammation, and hyperleptinemia.44
In the present study, the final multiple regression anal-
ysis showed that triglycerides, total cholesterol, and LDL-C
were positive predictors of TBARs. In addition, this studyTable 6 Some statistically significant correlations in all
studied obese participants.
Parameters r p
Serum adiponectin with:
Systolic blood pressure 0.379 0.016
Diastolic blood pressure 0.391 0.013
Body mass index 0.487 0.001
Waist circumference 0.524 0.001
High density lipoprotein cholesterol 0.472 0.002
Urinary gamma glutamyl transferase 0.542 <0.001
Serum thiobarbituric acid
reactive substances
0.624 <0.001
Serum thiobarbituric acid reactive substances with:
Systolic blood pressure 0.636 <0.001
Diastolic blood pressure 0.610 <0.001
Body mass index 0.615 <0.001
Waist circumference 0.514 0.001
High density lipoprotein cholesterol 0.529 <0.001
Urinary gamma glutamyl transferase 0.524 0.001
Urinary gamma glutamyl transferase with:
Body mass index 0.558 <0.001
Waist circumference 0.474 0.002
High density lipoprotein cholesterol 0.385 0.014
Urinary albumin/creatinine ratio 0.354 0.025
Body mass index with:
Waist circumference 0.659 <0.001
Systolic blood pressure 0.455 0.003
Diastolic blood pressure 0.362 0.022demonstrated a significant inverse correlation between
TBARs and both adiponectin and HDL-C, and a significant
positive correlation between adiponectin and HDL-C. These
results were also proved by the final multiple regression
analysis when using TBARs or adiponectin as a dependent
variable. Similar results have been shown in other
studies.45,46 The present results indicate that the increased
OS in obese individuals can be explained by the decreased
adiponectin level that may lead to deficiency of the
protective HDL-C. As it was found that there is a strong
inverse association between adiponectin and fractional
catabolic rate of ApoA-1 which is a major structural apoli-
poprotein of HDL-C.47 Deficiency of HDL-C in obese indi-
viduals was associated with elevated levels of oxidative
stress and impairment of its antioxidant effects.48
In this work, albuminuria was positively correlated with
TBARs and negatively correlated with adiponectin. These
results were also confirmed on using the final multiple
regression analysis which showed that ACR was a positive
predictor of TBARs in the obese group with normal AER, and
was a negative predictor of adiponectin in both obese
groups with normal and increased AER. Similarly, an inverse
association between adiponectin and albuminuria has been
previously demonstrated in other studies.49,50 A previous
experimental study has demonstrated that adiponectin
deficient mice exhibited increased albuminuria and fusion
of podocyte foot processes, which indicates that adipo-
nectin deficiency contributes to altered permeability,
probably via podocyte dysfunction.5 One potential pathway
by which adiponectin may provide protection against
albuminuria and podocyte permeability is via reduction of
OS.5,51,52
In the current study, albuminuria was associated with
systolic and diastolic blood pressure. A similar association
has been reported in other studies.53,54 Increased intra-
glomerular pressure is considered a major factor forTable 7 Some statistically significant correlations in the
studied obese participants with abnormal albumin excretion
rate.
Parameters r p
Urinary albumin/creatinine ratio with:
Systolic blood pressure 0.668 0.001
Diastolic blood pressure 0.637 0.003
Body mass index 0.605 0.005
Adiponectin 0.749 <0.001
Serum thiobarbituric
acid reactive substances
0.685 <0.001
Table 8 The final multiple regression analyses in all studied participants (n Z 60).
Significance t Beta B Significant predictors Dependent variables
1. BMI
0.040 2.104 17.702 Constant r Z 0.878, r2 Z 0.77, adjusted r2 Z 0.749,
ANOVA shows F Z 36.19, p < 0.0010.030 2.235 0.285 0.171 Systolic blood pressure
0.045 2.057 0.161 1.742 Uric acid
0.000 7.591 0.682 1.128 TBARs
2. Adiponectin
0.000 8.951 9.716 Constant r Z 0. 55, r2 Z 0.302, adjusted r2 Z 0.278,
ANOVA shows Fv12.337, p < 0.0000.001 3.602 0.428 0.233 TBARs
3. TBARs
0.655 0.450 1.791 Constant r Z 0. 9, r2 Z 0.81, adjusted r2 Z 0.789,
ANOVA shows F Z 37.661, p < 0.0000.000 4.331 0.413 0.250 BMI
0.001 3.437 0.269 0.097 Systolic blood pressure
0.017 2.454 0.192 0.034 UGGT
0.024 2.320 0.168 0.098 HDL-C
0.054 1.893 0.131 0.241 Adiponectin
4. UGGT
0.681 0.414 14.642 Constant r Z 0.73, r2 Z 0.533, adjusted r2 Z 0.489,
ANOVA shows F Z 12.31, P<0.0000.045 2.049 0.534 0.486 Waist circumference
0.004 2.990 0.450 2.522 TBARs
B Z regression coefficient; Beta Z standardized coefficient; BMI Z body mass index; HDL-C Z high density lipoprotein cholesterol;
TBARs Z serum thiobarbituric acid reactive substances; UGGT Z urinary gamma glutamyl transferase.
44 E.W. Gaber et al.increased albumin excretion in hypertension. In addition,
other factors such as decreased lysosomal activity with an
upregulation of transforming growth factor-b1 resulting in
increased albumin excretion in hypertension.55Table 9 The final multiple regression analyses in obese partici
Significance t Beta B Significant
0.154 1.520 18.867 Constant
0.000 5.616 1.182 1.866 TBARs
0.001 4.195 56.824 Constant
0.000 5.201 0.998 0.187 Waist circu
0.003 3.961 0.953 1.714 ACR
0.003 3.724 0.615 0.050 Cholesterol
0.569 0.594 3.763 Constant
0.000 11.103 0.541 0.343 BMI
0.001 5.305 0.186 0.056 Systolic blo
0.001 5.586 0.314 0.232 HDL-C
0.000 12.482 0.428 0.059 LDL-C
0.001 5.576 0.252 0.029 Triglyceride
0.039 2.466 0.145 0.436 ACR
0.001 5.132 0.239 0.037 UGGT
0.009 3.268 388.97 Constant
0.001 4.53 0.76 1.545 Waist circu
0.01 3.247 1.44 1.265 Cholesterol
0.06 2.062 0.36 7.033 ACR
0.001 5.032 1.338 8.671 TBARs
ACR Z urinary albumin/creatinine ratio; B Z regression coefficient;
C Z high-density lipoprotein cholesterol; LDL-C Z low-density lipop
substances; UGGT Z Urinary gamma glutamyl transferase.The presence of increased proximal tubular enzymuria
may be a surrogate marker of early renal injury to identify
individuals who are at risk for renal disease with early
intervention to prevent progression.56 In the currentpants with normal albumin excretion rate (n Z 20).
predictors Dependent variables
1. BMI
r Z 0.941, r2 Z 0.885, adjusted r2 Z 0.818,
ANOVA shows F Z 36.193, p < 0.001
2. Adiponectin
r Z 0.944, r2 Z 0.891, adjusted r2 Z 0.828
ANOVA shows F Z 14.07, p < 0.0001mference
3. TBARs
r Z 0.998, r2 Z 0.996, adjusted r2 Z 0.991,
ANOVA shows F Z 182.6, p < 0.0001
od pressure
s
4. UGGT
r Z 0.985, r2 Z 0.971, adjusted r2 Z 0.939,
ANOVA shows F Z 30.04, p < 0.0001mference
Beta Z standardized coefficient; BMI Z body mass index; HDL-
rotein cholesterol; TBARs Z Serum thiobarbituric acid reactive
Table 10 The final multiple regression analyses in obese participants with increased albumin excretion rate (n Z 20).
Significance t Beta B Significant predictors Dependent variables
1. BMI
0.000 32.026 42.985 Constant r Z 0.551, r2 Z 0.303, adjusted r2 Z 0.265,
ANOVA shows F Z 7.837, p < 0.0120.012 2.799 0.551 0.83 Adiponectin
2. Adiponectin
0.585 0.572 4.108 Constant r Z 0.978, r2 Z 0.956, adjusted r2 Z 0.88
ANOVA shows F Z 12.606, p < 0.0010.008 3.633 0.554 0.138 HDL-C
0.048 2.426 1.485 0.097 LDL-C
0.002 4.722 1.699 0.059 ACR
0.028 2.755 0.703 0.306 TBARs
3. TBARs
0.292 1.14 22.042 Constant r Z 0. 984, r2 Z 0.967, adjusted r2 Z 0.911,
ANOVA shows F Z 17.247, p < 0.00010.05 2.36 0.445 0.679 BMI
0.001 5.724 1.139 0.423 Systolic blood
pressure
0.003 4.488 0.779 0.473 FSG
0.005 4.036 1.554 0.211 Cholesterol
0.05 2.37 0.383 0.048 Triglycerides
0.012 3.371 0.796 0.468 eGFR
0.034 2.629 0.354 0.813 Adiponectin
0.012 3.354 0.434 0.063 UGGT
4. UGGT
0.683 0.42 50.809 Constant r Z 0.942, r2 Z 0.888, adjusted r2 Z 0.786,
ANOVA shows F Z 8.766, p < 0.0010.024 2.657 0.434 0.452 LDL-C
0.001 4.357 1.201 0.665 ACR
0.002 4.112 0.843 5.842 TBARs
ACR Z Urinary albumin/creatinine ratio; B Z regression coefficient; Beta Z standardized coefficient; BMI Z body mass index;
HDL-CZ high-density lipoprotein cholesterol; LDL-CZ low-density lipoprotein cholesterol; eGFRZ estimated glomerular filtration rate;
FSG Z fasting serum glucose; TBARs Z serum thiobarbituric acid reactive substances; UGGT Z urinary gamma glutamyl transferase.
Renal tubular dysfunction in obesity 45study, obese patients with normal AER manifested renal
tubular disorder evidenced by a significant increase in
UGGT. Also, the final multiple regression analysis revealed
that WC was a significant positive predictor of UGGT. In
addition, obese patients with increased AER had
concomitant renal tubular disorder evidenced by high
UGGT and ACR was proved to be a significant positive
predictor of UGGT in the final multiple regression analysis.
In line with these results, increased UGGT has been re-
ported in diabetic nephropathy.57 The increased UGGT can
be used as a simple, reliable, and noninvasive marker of
early tubular involvement in the preclinical stage of
obesity related nephropathy.
In the current study, TBARs were positively correlated
with BMI, ACR and UGGT. These results suggest that obesity
induced OS was accompanied by the occurrence of renal
tubular damage and increased glomerular permeability as
demonstrated by increased UGGT and albuminuria respec-
tively. Similar association between OS, tubular enzymuria
and increase in albuminuria has been reported with intra-
venous iron in patients with chronic kidney disease.58
The final multiple regression analysis confirmed that
TBARs and UGGT were significant positive predictors of
each other in all studied participants and in both obese
groups with normal and increased AER. OS-induced tubular
damage can be explained by the role of OS in the initiation
and propagation of apoptosis in various cell types, as has
been reported in other studies.59 The proximal tubule is
a major site of ROS production, due to its high transportactivity supported by oxygen consuming metabolism, ROS
and their products play an important role in apoptosis of
proximal tubular cells (PTC).60 Moreover, the presence of
albuminuria and exposure of the PTC to an excess
of albumin can induce renal proximal tubular cells
apoptosis through generation of ROS.61
In addition, the final multiple regression analysis showed
that eGFR was a negative predictor of TBARs in obese
individuals with increased AER. Exposure of PTC to patho-
logically high concentrations of urinary proteins, including
albumin, induces a number of potentially injurious biologic
responses in tubular epithelial cells, including inflamma-
tion, apoptosis, production of ROS, and transition to
a myofibroblast phenotype, ultimately contributing to
tubulo-interstitial fibrosis and ESRD.62
Conclusion
Glomerular and tubular dysfunctions in obese individuals
are related to low adiponectin and HDL-C levels and to
oxidative stress. Tubular dysfunction precedes MA so UGGT
may be used as an early marker for obesity related
nephropathy.
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